Institution
Humboldt University of Berlin
Education•Berlin, Germany•
About: Humboldt University of Berlin is a education organization based out in Berlin, Germany. It is known for research contribution in the topics: Population & Transplantation. The organization has 33671 authors who have published 61781 publications receiving 1908102 citations. The organization is also known as: Humboldt-Universität zu Berlin & Universitas Humboldtiana Berolinensis.
Papers published on a yearly basis
Papers
More filters
•
03 Jul 2018
TL;DR: This paper introduces a new anomaly detection method—Deep Support Vector Data Description—, which is trained on an anomaly detection based objective and shows the effectiveness of the method on MNIST and CIFAR-10 image benchmark datasets as well as on the detection of adversarial examples of GTSRB stop signs.
Abstract: Despite the great advances made by deep learning in many machine learning problems, there is a relative dearth of deep learning approaches for anomaly detection. Those approaches which do exist involve networks trained to perform a task other than anomaly detection, namely generative models or compression, which are in turn adapted for use in anomaly detection; they are not trained on an anomaly detection based objective. In this paper we introduce a new anomaly detection method—Deep Support Vector Data Description—, which is trained on an anomaly detection based objective. The adaptation to the deep regime necessitates that our neural network and training procedure satisfy certain properties, which we demonstrate theoretically. We show the effectiveness of our method on MNIST and CIFAR-10 image benchmark datasets as well as on the detection of adversarial examples of GTSRB stop signs.
1,070 citations
••
TL;DR: The 3.2 Å crystal structure of the bovine Ops*–GαCT peptide complex is presented and signal transfer from the receptor to the G protein nucleotide-binding site is discussed.
Abstract: Opsin, the ligand-free form of the G-protein-coupled receptor rhodopsin, at low pH adopts a conformationally distinct, active G-protein-binding state known as Ops*. A synthetic peptide derived from the main binding site of the heterotrimeric G protein-the carboxy terminus of the alpha-subunit (GalphaCT)-stabilizes Ops*. Here we present the 3.2 A crystal structure of the bovine Ops*-GalphaCT peptide complex. GalphaCT binds to a site in opsin that is opened by an outward tilt of transmembrane helix (TM) 6, a pairing of TM5 and TM6, and a restructured TM7-helix 8 kink. Contacts along the inner surface of TM5 and TM6 induce an alpha-helical conformation in GalphaCT with a C-terminal reverse turn. Main-chain carbonyl groups in the reverse turn constitute the centre of a hydrogen-bonded network, which links the two receptor regions containing the conserved E(D)RY and NPxxY(x)(5,6)F motifs. On the basis of the Ops*-GalphaCT structure and known conformational changes in Galpha, we discuss signal transfer from the receptor to the G protein nucleotide-binding site.
1,069 citations
••
TL;DR: In this article, the authors used a unique data set from West Germany that enabled them to look at how skill requirements have changed within occupations and found that occupations require more complex skills today than in 1979 and that the changes in skill requirements were most pronounced in rapidly computerizing occupations.
Abstract: Empirical work has been limited in its ability to directly study whether skill requirements in the workplace have been rising and whether these changes have been related to technological change. This article answers these questions using a unique data set from West Germany that enabled me to look at how skill requirements have changed within occupations. I show that occupations require more complex skills today than in 1979 and that the changes in skill requirements have been most pronounced in rapidly computerizing occupations. Changes in occupational content account for about 36% of the recent educational upgrading in employment.
1,069 citations
••
TL;DR: The application, advancement and future directions of SFF techniques in the design and creation of scaffolds for use in clinically driven tissue engineering are reviewed.
1,067 citations
••
Jagiellonian University1, University of Glasgow2, Queen Mary University of London3, Vanderbilt University Medical Center4, University of Manchester5, University of Naples Federico II6, University of Roehampton7, University of Texas at Austin8, Jagiellonian University Medical College9, Humboldt University of Berlin10, Huazhong University of Science and Technology11, Catholic University of the Sacred Heart12
TL;DR: While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis, Hence, patients should not discontinue their use.
Abstract: The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
1,060 citations
Authors
Showing all 34115 results
Name | H-index | Papers | Citations |
---|---|---|---|
Karl J. Friston | 217 | 1267 | 217169 |
Peer Bork | 206 | 697 | 245427 |
Raymond J. Dolan | 196 | 919 | 138540 |
Stefan Schreiber | 178 | 1233 | 138528 |
Andreas Pfeiffer | 149 | 1756 | 131080 |
Thomas Hebbeker | 148 | 1984 | 114004 |
Thomas Lohse | 148 | 1237 | 101631 |
Jean Bousquet | 145 | 1288 | 96769 |
Hermann Kolanoski | 145 | 1279 | 96152 |
Josh Moss | 139 | 1019 | 89255 |
R. D. Kass | 138 | 1920 | 107907 |
W. Kozanecki | 138 | 1498 | 99758 |
U. Mallik | 137 | 1625 | 97439 |
C. Haber | 135 | 1507 | 98014 |
Christophe Royon | 134 | 1453 | 90249 |